Ali YalcindagAssociate Professor of Pediatrics (Clinical)
A member of the Brown faculty since 2003, Ali Yalcindag, MD is a graduate of Cerrahpasa Faculty of Medicine of Istanbul University. After completing a residency in Pediatrics at NYU Medical Center, he completed a fellowship in the Division of Immunology at Boston Children’s Hospital. Currently, he is the Director of Division of Pediatric Rheumatology at Hasbro Children’s Hospital.
Yalcindag A, Bloom BJ, Alario AJ. Rheumatic Disorders, Book Chapter in Practical Guide to The Care of the Pediatric Patient. 2nd ed 2008
Yalcindag A, Sundel R. Serum Sickness. Book chapter in Current Pediatric Therapy, 17th ed, 2002.
Yalcindag A; Sundel R. Vasculitis in Childhood. Current Opinion in Rheumatology. 2001; Sep 13(5): 422-27.
My earlier research focused on a mouse model of atopic dermatitis, a condition characterized by chronic allergic inflammation of skin. Using a mouse model that mimics human atopic dermatitis developed in the laboratory of Dr. Raif Geha at Boston Children's Hospital, I tried to identify the mechanisms by which the immune sytem responds to substances introduced through the skin. Specifically, I studied the role of substances called complements in directing and changing the immune response.
My current clinical reasearch interest is in the area of pediatric rheumatology. I serve as the site PI for the multicenter collaborative registry (CARRA Registry). The CARRA Registry is an observational study that enrolls children and adolescents with major rheumatic diseases followed at participating study sites. The original "Legacy" CARRA Registry is now complete and enrolled 9587 patients.
Using a mouse model of atopic dermatitis, I studied the role of complement proteins and their recptors in modulating the immune response. I demonstrated that the complement proteinn C3a downregulates the Th2 response to epicutaneously introduced antigens suggesting an important role for complement proteins in T cell polarization. Furthermore, I conducted experiments to show that C3 is important for both Th1 and Th2 immune responses.
In the original CARRA registry, we collected data on children followed by Hasbro Children's Hopsital Rheumatology clinic. The new CARRA Registry started enrolling patients in the summer of 2015. Continuation of the CARRA Registry will support data collection on patients with pediatric-onset rheumatic diseases and will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions. Our site got activated in April 2016.